Do you foresee any added benefit of triple agonist therapy (GLP-1, GIP and glucagon) for glycemic control in patients with Type 1 diabetes mellitus?

There are a number of triple agonists under development. Furthest along is retatrutide with average weight loss approaching 30% in the setting of obesity. GLP-1 receptor agonists have definitively demonstrated weight loss benefits in people living with type 1 diabetes. Glycemic benefits have emerged...

This is actually a speculative question, given that there is no available data to address this. But what data do we have that might inform a decision to use a triple agonist in the T1DM patient population? A recent NEJM Evidence article (Shah et al., PMID 40550013) looked at the use of semaglutide, ...

This is an interesting question. Since glucagon receptor therapy has not been tested in type 1 diabetes, let me address your question based on what we know of the physiology. Isolated glucagon receptor agonism increases hepatic glucose production and causes hyperglycemia. However, glucagon receptor ...